Novavax vs Pfizer Which Is Superior?

Novavax and Pfizer are two leading pharmaceutical companies that have been at the forefront of developing COVID-19 vaccines. Novavax has gained attention for its promising vaccine candidate, NVX-CoV2373, while Pfizer has already released its widely-used vaccine, BNT162b2. Both companies have seen their stocks fluctuate as vaccine distribution efforts continue worldwide. Investors are closely monitoring the progress of these companies in the competitive market, as they navigate the challenges and opportunities presented by the pandemic.

Novavax or Pfizer?

When comparing Novavax and Pfizer, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Novavax and Pfizer.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Novavax has a dividend yield of -%, while Pfizer has a dividend yield of 6.4%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Novavax reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of 221.76%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Novavax P/E ratio at -4.54 and Pfizer's P/E ratio at 34.91. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Novavax P/B ratio is -3.10 while Pfizer's P/B ratio is 1.61.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Novavax has seen a 5-year revenue growth of 4.26%, while Pfizer's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Novavax's ROE at 43.70% and Pfizer's ROE at 4.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $8.90 for Novavax and $26.22 for Pfizer. Over the past year, Novavax's prices ranged from $3.53 to $23.86, with a yearly change of 575.92%. Pfizer's prices fluctuated between $25.20 and $31.54, with a yearly change of 25.16%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.